BAFNAPH - Bafna Pharmaceuticals Limited Share Price

Pharmaceuticals & Biotechnology

₹172.14+7.13(+4.32%)

Market Closed as of Dec 24, 2025, 15:30 IST

Pros

Balance Sheet: Strong Balance Sheet.

Smart Money: Smart money is taking extra interest in the stock as they increase their holdings.

Momentum: Stock price has a strong positive momentum. Stock is up 5% in last 30 days.

Buy Backs: Company has bought back it's stock in the past which is a good thing.

Cons

Dividend: Stock hasn't been paying any dividend.

Size: It is a small market cap company and can be volatile.

Valuation
Market Cap	407.22 Cr
Price/Earnings (Trailing)	46.52
Price/Sales (Trailing)	2.8
EV/EBITDA	26.29
Price/Free Cashflow	1.26 K
MarketCap/EBT	46.42
Enterprise Value	439.37 Cr

Fundamentals
Revenue (TTM)	145.33 Cr
Rev. Growth (Yr)	-11.4%
Earnings (TTM)	8.77 Cr
Earnings Growth (Yr)	19.4%

Profitability
Operating Margin	7%
EBT Margin	6%
Return on Equity	9.62%
Return on Assets	5.46%
Free Cashflow Yield	0.08%

Price to Sales Ratio

Latest reported: 2.8

Revenue (Last 12 mths)

Latest reported: 145.3 Cr

Net Income (Last 12 mths)

Latest reported: 8.8 Cr

Growth & Returns
Price Change 1W	19.6%
Price Change 1M	5%
Price Change 6M	115.1%
Price Change 1Y	115%
3Y Cumulative Return	20.2%
5Y Cumulative Return	0.00%
7Y Cumulative Return	47.3%
10Y Cumulative Return	14.4%

Cash Flow & Liquidity
Cash Flow from Investing (TTM)	-21.16 Cr
Cash Flow from Operations (TTM)	22.14 Cr
Cash Flow from Financing (TTM)	1.06 Cr
Cash & Equivalents	25.44 L
Free Cash Flow (TTM)	27.62 L
Free Cash Flow/Share (TTM)	0.12

Balance Sheet
Total Assets	160.68 Cr
Total Liabilities	69.45 Cr
Shareholder Equity	91.23 Cr
Current Assets	80.07 Cr
Current Liabilities	47.82 Cr
Net PPE	65 Cr
Inventory	31 Cr
Goodwill	0.00

Capital Structure & Leverage
Debt Ratio	0.2
Debt/Equity	0.36
Interest Coverage	1.72
Interest/Cashflow Ops	8.41

Dividend & Shareholder Returns
Shares Dilution (1Y)	0.00%
Shares Dilution (3Y)	0.00%

Pros

Balance Sheet: Strong Balance Sheet.

Smart Money: Smart money is taking extra interest in the stock as they increase their holdings.

Momentum: Stock price has a strong positive momentum. Stock is up 5% in last 30 days.

Buy Backs: Company has bought back it's stock in the past which is a good thing.

Cons

Dividend: Stock hasn't been paying any dividend.

Size: It is a small market cap company and can be volatile.

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Rank

Balance Sheet

Momentum

Technicals

Smart Money

Insider Trading

Investor Care
Shares Dilution (1Y)	0.00%
Earnings/Share (TTM)	3.7

Financial Health
Current Ratio	1.67
Debt/Equity	0.36

Technical Indicators
RSI (14d)	67.89
RSI (5d)	100
RSI (21d)	50.73
MACD Signal	Buy
Stochastic Oscillator Signal	Hold
Grufity Signal	Buy
RSI Signal	Hold
RSI5 Signal	Sell
RSI21 Signal	Hold
SMA 5 Signal	Buy
SMA 10 Signal	Buy
SMA 20 Signal	Buy
SMA 50 Signal	Buy
SMA 100 Signal	Buy

Earnings Outlook

Last updated:

Q&A Session

Last updated:

Share Holdings

Understand Bafna Pharmaceuticals ownership landscape with insights into key distribution patterns, offering investors a clear view of stakeholder dynamics.

Holding Pattern

Major Shareholders

Share Holding Details

Shareholder Name	Holding %
SRJR LIFESCIENCES LLP	74.57%
ALPANA MUNDRA	3.25%
M7 GLOBAL FUND PCC-AERION	3.21%
M7 GLOBAL FUND PCC - CELL DEWCAP FUND	3.12%
ZEAL GLOBAL OPPORTUNITIES FUND	3.01%
MONARCH NETWORTH FINSERVE PRIVATE LIMITED	1.35%
GUTTIKONDA VARA LAKSHMI	1.29%
P PARAS BAFNA	0.21%
NAVIN BAFNA	0.18%
MAHAVEER CHAND BAFNA	0.03%
SASIKALA BAFNA	0.01%
AMRI BAI BAFNA	0.01%
CHETNA BAFNA	0%
MAHAVEER CHAND BAFNA HUF	0%
PARAS BAFNA	0%

Overall Distribution

Distribution across major stakeholders

Ownership Distribution

Distribution across major institutional holders

Ticker	Name	Mkt Cap	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
		-	-	-	-	-	-	-	-

Category	BAFNAPH	Pharmaceuticals
PE	44.60	35.23
PS	2.69	4.96
Growth	-0.8 %	10.3 %

Key Insights

1. BAFNAPH is NOT among the Top 10 largest companies in Pharmaceuticals.
2. The company holds a market share of 0% in Pharmaceuticals.
3. In last one year, the company has had a below average growth that other Pharmaceuticals companies.

Description	(%) Q/Q	Mar-2025	Mar-2024	Mar-2023	Mar-2022	Mar-2021	Mar-2020
Revenue From Operations	-	-	-	-	-	-	42
Other Income	-	-	-	-	-	-	0.26
Total Income	-	-	-	-	-	-	43
Cost of Materials	-	-	-	-	-	-	30
Purchases of stock-in-trade	-	-	-	-	-	-	0.02
Employee Expense	-	-	-	-	-	-	10
Finance costs	-	-	-	-	-	-	0.1
Depreciation and Amortization	-	-	-	-	-	-	3.27
Other expenses	-	-	-	-	-	-	3.97
Total Expenses	-	-	-	-	-	-	45
Profit Before exceptional items and Tax	-	-	-	-	-	-	-1.88
Exceptional items before tax	-	-	-	-	-	-	-22.56
Total profit before tax	-	-	-	-	-	-	-24.44
Deferred tax	-	-	-	-	-	-	0
Total tax	-	-	-	-	-	-	0
Total profit (loss) for period	-	-	-	-	-	-	-24.73
Other comp. income net of taxes	-	-	-	-	-	-	0
Total Comprehensive Income	-	-	-	-	-	-	-24.73
Earnings Per Share, Basic	-	-	-	-	-	-	-15.52
Earnings Per Share, Diluted	-	-	-	-	-	-	-15.52

Description	(%) Q/Q	Mar-2025	Mar-2024	Mar-2023	Mar-2022	Mar-2021	Mar-2020
Revenue From Operations	-4%	146	152	115	85	71	42
Other Income	-31%	2.74	3.52	3.27	2.1	0.75	0.26
Total Income	-4.5%	149	156	119	87	72	43
Cost of Materials	-6.4%	74	79	60	53	43	30
Purchases of stock-in-trade	-108.3%	0	13	6.41	0	0	0.02
Employee Expense	11.1%	21	19	16	14	12	10
Finance costs	34.1%	2.73	2.29	2.04	0.79	0.74	0.1
Depreciation and Amortization	-2.8%	4.89	5	5.33	5.49	4.48	3.27
Other expenses	-8.6%	33	36	21	7.86	3.48	3.97
Total Expenses	-4.7%	142	149	107	80	66	45
Profit Before exceptional items and Tax	-16.5%	6.3	7.35	12	7.31	5.83	-1.88
Exceptional items before tax	-	-2.15	0	0	-2.16	0	-23.33
Total profit before tax	-50.4%	4.15	7.35	12	5.15	5.83	-25.2
Current tax	-	0	0	0.28	0	0	0
Deferred tax	-	0	0	0	0	0	0
Total tax	-	0	0	0.28	0	0	0
Total profit (loss) for period	-50.4%	4.15	7.35	11	5.15	5.83	-25.2
Other comp. income net of taxes	-22.9%	-0.18	0.04	0.15	-0.02	0	0
Total Comprehensive Income	-53.4%	3.97	7.38	11	5.13	5.83	-25.2
Earnings Per Share, Basic	-64%	1.76	3.11	4.86	4.34	2.46	-106.54
Earnings Per Share, Diluted	-64%	1.76	3.11	4.86	4.34	2.46	-106.54

Description	(%) Q/Q	Sep-2025	Jun-2025	Mar-2025	Dec-2024	Sep-2024	Jun-2024
Revenue From Operations	0%	35	35	39	33	40	33
Other Income	145%	1.18	0.6	1.02	0.19	1.02	0.51
Total Income	5.9%	37	35	40	33	41	34
Cost of Materials	5.9%	19	18	17	17	22	18
Purchases of stock-in-trade	-	0.63	0	0	0	0	0
Employee Expense	-3.2%	5.49	5.64	5.58	5.26	5.06	5.14
Finance costs	-55.6%	0.86	0.91	0.82	0.64	0.62	0.65
Depreciation and Amortization	27%	1.47	1.37	0.22	1.66	1.57	1.44
Other expenses	18.8%	7.63	6.58	8.82	7.12	9.68	7.1
Total Expenses	6.5%	34	32	37	32	39	34
Profit Before exceptional items and Tax	-11.3%	3.12	3.39	3.1	0.96	2.62	-0.38
Exceptional items before tax	-	0	0	-1.79	-0.01	0	-0.34
Total profit before tax	-11.3%	3.12	3.39	1.31	0.95	2.62	-0.72
Total profit (loss) for period	-11.3%	3.12	3.39	1.31	0.95	2.62	-0.72
Other comp. income net of taxes	0%	-0.05	-0.05	-0.21	0.01	0.01	0.01
Total Comprehensive Income	-11.1%	3.08	3.34	1.1	0.96	2.63	-0.71
Earnings Per Share, Basic	-25.6%	1.32	1.43	0.55	0.4	1.11	-0.31
Earnings Per Share, Diluted	-25.6%	1.32	1.43	0.55	0.4	1.11	-0.31

Description	(%) Q/Q	Sep-2025	Mar-2025	Sep-2024	Mar-2024	Sep-2023	Mar-2023
Cash and cash equivalents	-130.9%	0.25	3.43	1.31	1.4	7.86	7.81
Loans, current	9.2%	0.11	0.02	0.07	0.08	0.17	0.05
Total current financial assets	-20.9%	35	44	35	48	48	49
Inventories	11.1%	31	28	27	30	29	22
Current tax assets	5.7%	0.34	0.3	0.72	0.65	0.59	0.47
Total current assets	-6%	80	85	75	94	91	87
Property, plant and equipment	10.3%	65	59	54	40	39	40
Capital work-in-progress	121.9%	15	7.31	1.57	10	1.77	1.5
Total non-current financial assets	73.7%	0.95	0.81	0.8	0.73	0.69	0.54
Total non-current assets	21.2%	81	67	58	53	44	42
Total assets	5.3%	161	153	134	148	135	130
Borrowings, non-current	38.5%	19	14	11	11	7.11	8.43
Total non-current financial liabilities	38.5%	19	14	11	11	8.28	9.65
Provisions, non-current	0%	0.48	0.48	0.57	0.39	0	0
Total non-current liabilities	40%	22	16	13	13	8.28	9.65
Borrowings, current	-7.7%	13	14	7.5	14	9.47	14
Total current financial liabilities	-12.8%	42	48	34	51	40	44
Provisions, current	65.8%	1.63	1.38	1.26	1.26	0.46	0.63
Total current liabilities	-7.8%	48	52	38	54	44	46
Total liabilities	1.5%	69	68	51	67	53	56
Equity share capital	0%	24	24	24	24	24	24
Total equity	7.1%	91	85	83	81	82	73
Total equity and liabilities	5.3%	161	153	134	148	135	130

Description	(%) Q/Q	Mar-2025	Mar-2024	Mar-2023	Mar-2022	Mar-2021	Mar-2020
Finance costs	34.1%	2.73	2.29	1.8	0	0.09	-
Change in inventories	102.1%	1.18	-7.42	-1.94	-4.84	-4.03	-
Depreciation	-2.8%	4.89	5	5.33	5.49	4.48	-
Adjustments for interest income	1.1%	0.14	0.13	0.03	0	0	-
Net Cashflows from Operations	142.5%	22	9.66	5.08	9.39	-11.01	-
Interest paid	-	0	0	0	0.79	0.09	-
Interest received	-	0	0	0	0	-0.04	-
Income taxes paid (refund)	-62.7%	-0.35	0.17	0.13	0	0	-
Other inflows (outflows) of cash	-	0	0	0	-2.06	2.5	-
Net Cashflows From Operating Activities	147.6%	22	9.48	4.95	6.53	-8.64	-
Proceeds from sales of PPE	-13.3%	0.06	0.17	0.2	0	0	-
Purchase of property, plant and equipment	40%	22	16	6.72	7.54	-6.09	-
Purchase of intangible assets under development	-37%	0	0.27	1.5	0	0	-
Proceeds from government grants	0%	0.5	0.5	0	0.98	0	-
Interest received	2.3%	0.14	0.12	0.03	-0.04	0.04	-
Other inflows (outflows) of cash	-	0	0	0.5	2.06	0	-
Net Cashflows From Investing Activities	-38.1%	-21.16	-15.05	-7.49	-4.54	6.13	-
Proceeds from borrowings	497.9%	3.81	1.47	12	5.39	2.5	-
Repayments of borrowings	-	0	0	0	9.8	-9.87	-
Interest paid	33.6%	2.75	2.31	1.69	-0.79	0	-
Net Cashflows from Financing Activities	103.2%	1.06	-0.85	10	-3.62	12	-
Effect of exchange rate on cash eq.	-	0	0	0	0	0.42	-
Net change in cash and cash eq.	114%	2.04	-6.41	7.64	-1.63	10	-

Bafna Pharmaceuticals Limited manufactures and sells finished pharmaceutical formulations in India. It also exports its products to Europe, the United Kingdom, Australia, Sri Lanka, Africa, and internationally. The company was founded in 1981 and is based in Chennai, India. Bafna Pharmaceuticals Limited operates as a subsidiary of SRJR Lifesciences LLP.

Industry Group:Pharmaceuticals & Biotechnology

Employees:363

Website:www.bafnapharma.com

Important Disclosure & Data Context

This is an informational page just to provide a quick 'first look' at the stock. You must do your own deeper research. Know your risk appetite. Consult a SEBI-registered financial advisor before making any investment decisions.

BAFNAPH - Bafna Pharmaceuticals Limited Share Price

Valuation

Fundamentals

Profitability

Price to Sales Ratio

Revenue (Last 12 mths)

Net Income (Last 12 mths)

Growth & Returns

Cash Flow & Liquidity

Balance Sheet

Capital Structure & Leverage

Dividend & Shareholder Returns

Investor Care

Financial Health

Technical Indicators

Share Holdings

Holding Pattern

Share Holding Details

Overall Distribution

Ownership Distribution

What does Bafna Pharmaceuticals Limited do?

Important Disclosure & Data Context

BAFNAPH - Bafna Pharmaceuticals Limited Share Price

BAFNAPH

Valuation

Fundamentals

Profitability

Price to Sales Ratio

Revenue (Last 12 mths)

Net Income (Last 12 mths)

Growth & Returns

Cash Flow & Liquidity

Balance Sheet

Capital Structure & Leverage

Dividend & Shareholder Returns

BAFNAPH

Investor Care

Financial Health

Technical Indicators

Share Holdings

Holding Pattern

Share Holding Details

Overall Distribution

Ownership Distribution

What does Bafna Pharmaceuticals Limited do?

Important Disclosure & Data Context

BAFNAPH

BAFNAPH